Chiropractors in Stanwood, MI Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Spine By Design Inc. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 10032 Buchanan Rd, Stanwood, MI 49346 Phone: 231-972-1144 Fax: 888-965-4351 |
Gregerson Radiology Consultants Ltd. Chiropractor - Radiology Medicare: Not Enrolled in Medicare Practice Location: 8004 Red Fox Rd, Stanwood, MI 49346 Phone: 630-854-3367 |
 Dr. Thomas Jorgen White, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 10032 Buchanan Rd, Stanwood, MI 49346 Phone: 231-972-1200 Fax: 888-965-5221 |
Routley Chiropractic Care Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 8540 105th Ave, Stanwood, MI 49346 Phone: 231-972-4141 Fax: 231-972-7507 |
News Archive
Patients undergoing eye trauma care fare equally well in teaching and community hospitals
Adding to evidence that "high-volume" specialty care in busy teaching hospitals leads to efficiencies unavailable in community hospitals, a new study by Johns Hopkins researchers finds that patients undergoing repair of traumatic eye socket injuries at its busy academic medical center fared just as well at far less cost than those treated at all other Maryland hospitals.
Brain imaging distinguishes Parkinson's subtypes
Patients with nontremor-dominant Parkinson's disease show changes in brain activity that set them apart from tremor-dominant patients and from healthy controls, a study shows.
Study results confirm safety and efficacy of INSIGHTEC's Exablate Neuro system for the treatment of essential tremor
INSIGHTEC, the leader in MR-guided Focused Ultrasound (MRgFUS) therapy, has announced that the New England Journal of Medicine (NEJM) has published the results of a pivotal study of their Exablate Neuro system for the non-invasive treatment of essential tremor (ET). The study met its primary endpoint with patients treated with Exablate Neuro demonstrating a clinically significant 47% improvement in a composite tremor score at three months as compared to no change in the sham cohort.
Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.
› Verified 9 days ago